Literature DB >> 25348169

Looking forward, looking back-10 years in urology.

Maarten Albersen1, Rufus Cartwright2, Peter Choyke3, S Larry Goldenberg4, Howard Goldman5, Nathan Lawrentschuk6, W Marston Linehan7, Declan Murphy8, Harris Nagler9, Peter Scardino10, Linda Shortliffe11, Arnulf Stenzl12, Dan Theodorescu13.   

Abstract

When Nature Reviews Urology launched in 2004, the field of urology was vastly different to that which we work in today, and the past 10 years have seen the field change immensely. As a specialty on the forefront of cutting-edge innovation, urologists are often the first to embrace new technologies and ideas. In this Viewpoint, members of the Nature Reviews Urology advisory board were asked what they thought was the most important change, issue or innovation in urology in the past 10 years, and what they expected to be the most important in the next decade. Here are their opinions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348169     DOI: 10.1038/nrurol.2014.263

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  21 in total

Review 1.  Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy.

Authors:  Ashutosh Tewari; Prasanna Sooriakumaran; Daniel A Bloch; Usha Seshadri-Kreaden; April E Hebert; Peter Wiklund
Journal:  Eur Urol       Date:  2012-02-24       Impact factor: 20.096

2.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

3.  Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men.

Authors:  Michael J Barry; Patricia M Gallagher; Jonathan S Skinner; Floyd J Fowler
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

Review 5.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

6.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

7.  The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury.

Authors:  Derek Bochinski; Gui Ting Lin; Lora Nunes; Rafael Carrion; Nadeem Rahman; Ching Shwun Lin; Tom F Lue
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Trends in androgen prescribing in the United States, 2001 to 2011.

Authors:  Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin
Journal:  JAMA Intern Med       Date:  2013-08-12       Impact factor: 21.873

10.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

View more
  3 in total

1.  Tissue engineering and regenerative medicine: bench to bedside in urology. Preface.

Authors:  Margot S Damaser; Karl-Dietrich Sievert
Journal:  Adv Drug Deliv Rev       Date:  2015-01-24       Impact factor: 15.470

2.  Open versus minimally invasive surgical approaches in pediatric urology: Trends in utilization and complications.

Authors:  Rohit Tejwani; Brian J Young; Hsin-Hsiao S Wang; Steven Wolf; J Todd Purves; John S Wiener; Jonathan C Routh
Journal:  J Pediatr Urol       Date:  2017-02-22       Impact factor: 1.830

Review 3.  Biofabrication and biomaterials for urinary tract reconstruction.

Authors:  Moustafa M Elsawy; Achala de Mel
Journal:  Res Rep Urol       Date:  2017-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.